The Impact of the NOD2/CARD15 Variant (3020insC) and PSMA6 Polymorphism (-8C>G) on the Development and Outcome of Multiple Myeloma

Table 2

Inclusion and exclusion criteria for MM patients and blood donors.

Inclusion criteria
MM patients	(i) Newly diagnosed MM patients who are required to start active treatment according to the IMWG published in 2014; (ii) Signed informed consent; (iii) Years after 18; (iv) Patients must have measurable disease, defined as follows: (a) For secretory MM, measurable disease is defined as the presence of quantifiable monoclonal component (≥0.5 g/dl); (b) For poor secretory or nonsecretory MM, the level of the affected serum free light chain must be ≥10 mg/dl (≥100 mg/l, with an abnormal free light chain ratio); (v) Eastern Cooperative Oncology Group (ECOG) performance; (vi) Life expectancy more than 3 months
Control group	(i) Age: 18 and older; (ii) Signed informed consent
Exclusion criteria
MM patients	(i) Active smoldering MM; (ii) Active plasma cell leukemia; (iii) Documented systemic amyloid light chain amyloidosis; (iv) Active central nervous system involvement with MM; (v) Active other hematologic malignancies or solid tumors
Control group	(i) Known to be infected with HIV, syphilis, tuberculosis, hepatitis B, or hepatitis C; (ii) A condition in which repeated blood draws or injections pose more than minimal risk for the subject such as hemophilia, other severe coagulation disorders, or significantly impaired venous access; (iii) A condition that requires active medical intervention or monitoring to avert serious danger to the participant’s health or well-being